← Leaderboards
Thomas D Bannister
H. Lee Moffitt Cancer Ctr & Res Inst
$24,896,252
Attributed
$35,987,592
Total exposure
13
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $14.6M · FY2010–25$20M$15M$10M$5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,987,592 · 13
By mechanism
R01$18,444,384 · 8
U19$13,141,857 · 1
RF1$1,878,085 · 1
R21$950,000 · 1
U01$907,100 · 1
R56$666,166 · 1
Top collaborators
- Laura M Bohn14 shared
- Derek Ronald Duckett10 shared
- Corinne Ida Lasmezas5 shared
- Patricia Helen Mcdonald3 shared
- Donghoon Chung2 shared
- Joseph Kissil2 shared
- Dahai Luo2 shared
- Michael Darin Cameron1 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoPharmaceutical ChemistryCellsSmall MoleculeDrug KineticsLeadPropertyBaseReceptorEvaluationBrainPharmacologySeriesStructureIn VitroFloridaScaffoldPharmaceutical PreparationsPreventSignal TransductionAffinityMolecularAgonistMouse Model
Grant awards (44)
Development of novel antivirals for arthritogenic alphaviruses$544,521
R01 · FY2025 · AI
Development of novel antivirals for arthritogenic alphaviruses$140,400
R01 · FY2025 · AI
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers$700,051
R01 · FY2023 · CA
Core C: Medicinal Chemistry and DMPK$13,141,857
U19 · FY2022 · AI · contact PI
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$736,212
R01 · FY2022 · DA
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers$700,051
R01 · FY2022 · CA
Early development of small molecule neuroprotectants.$733,123
R01 · FY2021 · NS
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers$714,336
R01 · FY2021 · CA
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$523,240
R01 · FY2021 · DA
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$212,972
R01 · FY2021 · DA
Early development of small molecule neuroprotectants.$767,106
R01 · FY2020 · NS
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$736,212
R01 · FY2020 · DA
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers$714,336
R01 · FY2020 · CA
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$22,800
R01 · FY2020 · DA
Early development of small molecule neuroprotectants.$777,326
R01 · FY2019 · NS
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$736,212
R01 · FY2019 · DA
Development and validation of small molecules to treat neurofibromatosis associated schwannoma$475,000
R21 · FY2019 · NS
Development of in vivo active small molecule selective inhibitors of ASK1$457,122
R01 · FY2019 · GM
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$22,200
R01 · FY2019 · DA
Development of in vivo active small molecule activators of Ulk1$1,878,085
RF1 · FY2018 · AG
Early development of small molecule neuroprotectants.$755,830
R01 · FY2018 · NS
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$736,212
R01 · FY2018 · DA
High Throughput Screening to Discover Small Molecule Modulators of the Orphan GPCR GPR151$563,962
R01 · FY2018 · MH · contact PI
Development of in vivo active small molecule selective inhibitors of ASK1$518,828
R01 · FY2018 · GM
Development and validation of small molecules to treat neurofibromatosis associated schwannoma$475,000
R21 · FY2018 · NS
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers$470,637
R01 · FY2018 · CA
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers$298,954
R01 · FY2018 · CA
Development of in vivo active small molecule selective inhibitors of ASK1$71,929
R01 · FY2018 · GM
Early development of small molecule neuroprotectants$666,166
R56 · FY2017 · NS
High Throughput Screening to Discover Small Molecule Modulators of the Orphan GPCR GPR151$563,962
R01 · FY2017 · MH
High Throughput Screening to Discover Small Molecule Modulators of the Orphan GPCR GPR151$870,985
R01 · FY2016 · MH
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$630,366
R01 · FY2016 · DA
Small molecule Nociceptin Receptor Agonists to Treat Cocaine Abuse$142,061
R01 · FY2016 · DA · contact PI
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$15,053
R01 · FY2016 · DA
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$622,873
R01 · FY2015 · DA
Small molecule Nociceptin Receptor Agonists to Treat Cocaine Abuse$141,343
R01 · FY2015 · DA · contact PI
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$644,021
R01 · FY2014 · DA
Small molecule Nociceptin Receptor Agonists to Treat Cocaine Abuse$143,497
R01 · FY2014 · DA · contact PI
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$613,852
R01 · FY2013 · DA
Small molecule Nociceptin Receptor Agonists to Treat Cocaine Abuse$137,757
R01 · FY2013 · DA · contact PI
Synthesis and Evaluation of Functionally Biased Opioid Analgesics$634,972
R01 · FY2012 · DA
Small molecule Nociceptin Receptor Agonists to Treat Cocaine Abuse$143,497
R01 · FY2012 · DA · contact PI
Discovery of potent and selective neuropeptide Y Y2 receptor antagonist probes$907,100
U01 · FY2010 · AA · contact PI
Discovery and development of nociceptin receptor ligands in alcohol dependence$485,573
R01 · FY2010 · AA · contact PI